Zealand Pharma A/S Q3 2025 Earnings Report

Zealand Pharma A/S EPS Results

• Actual EPS: -$0.90
• Consensus EPS: -$1.11
• Beat/Miss: Beat by +$0.21
• One Year Ago EPS: N/A

Zealand Pharma A/S Revenue Results

• Actual Revenue: $7.76 million
• Expected Revenue: $4.54 million
• Beat/Miss: Beat by +$3.22 million
• YoY Revenue Growth: N/A

Zealand Pharma A/S Announcement Details

• Quarter: Q3 2025
• Date: 11/13/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Zealand Pharma A/S (OTCMKTS:ZLDPF) is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. The company’s research programs address serious and underserved conditions, particularly metabolic diseases, gastrointestinal disorders and rare diseases. Zealand combines proprietary peptide technologies with drug-development expertise to create therapies designed to improve treatment outcomes and patient convenience.

Zealand’s commercial portfolio includes Zegalogue (dasiglucagon), an injectable treatment for severe hypoglycemia in people with diabetes. The company is also advancing a pipeline of investigational medicines, including treatments for obesity, metabolic dysfunction and other chronic conditions. Several programs are being developed through collaborations with international pharmaceutical companies, including a partnership with Boehringer Ingelheim for survodutide, an investigational medicine being studied in metabolic disease.

Founded in 1998, Zealand Pharma is headquartered in Søborg, Denmark, and serves international markets through its own commercial activities and strategic partnerships. The company’s leadership is headed by Chief Executive Officer Adam Steensberg, who has overseen the organization’s focus on late-stage development, commercialization and partnerships in metabolic and rare-disease medicine.